Related Experiment Video
Updated: May 16, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor
Ryoichi Kimura1, David MacTavish, Jing Yang
1Department of Medicine, Hyogo College of Medicine, Nishinomiya, 663-8501 Hyogo, Japan.
Abstract:
Alzheimer's disease (AD) is characterized by accumulation of amyloid-β peptide (Aβ) in the brain regions that subserve memory and cognition. The amylin receptor is a potential target receptor for expression of the deleterious actions of soluble oligomeric Aβ species. We investigated whether the amylin receptor antagonist, AC253, neutralizes the depressant effects of Aβ(1-42) and human amylin on hippocampal long-term potentiation (LTP). Furthermore, we examined whether depressed levels of LTP observed in transgenic mice, which overexpress amyloid precursor protein (TgCRND8), could be restored with AC253. In mouse hippocampal brain slices, field EPSPs were recorded from the stratum radiatum layer of the CA1 area (cornu ammonis 1 region of the hippocampus) in response to electrical stimulation of Schaeffer collateral afferents. LTP was induced by 3-theta burst stimulation protocols. Aβ(1-42) (50 nM) and human amylin (50 nM), but not Aβ(42-1) (50 nM), depressed LTP evoked using both stimulation protocols. Preapplication of AC253 (250 nM) blocked Aβ- and human amylin-induced reduction of LTP without affecting baseline transmission or LTP on its own. In contrast to wild-type controls, where robust LTP is observed, 6- to 12-month-old TgCRND8 mice show blunted LTP that is significantly enhanced by application of AC253. Our data demonstrate that the effects of Aβ(1-42) and human amylin on LTP are expressed via the amylin receptor, and moreover, blockade of this receptor increases LTP in transgenic mice that show increased brain amyloid burden. Amylin receptor antagonists could serve as potentially useful therapeutic agents in AD.
Insights
Alzheimer's disease involves amyloid-beta peptide (Aβ) buildup. An amylin receptor antagonist, AC253, reversed Aβ-induced memory impairment in mice, suggesting a new therapeutic target for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Alzheimer's disease (AD) is linked to amyloid-beta peptide (Aβ) accumulation in brain regions vital for memory and cognition.
- The amylin receptor is implicated in mediating the detrimental effects of soluble oligomeric Aβ species.
Purpose of the Study:
- To determine if the amylin receptor antagonist AC253 can counteract the negative effects of Aβ(1-42) and human amylin on hippocampal long-term potentiation (LTP).
- To investigate if AC253 can restore impaired LTP in TgCRND8 transgenic mice overexpressing amyloid precursor protein.
Main Methods:
- Field excitatory postsynaptic potentials (fEPSPs) were recorded in mouse hippocampal slices (CA1 region).
- Long-term potentiation (LTP) was induced using theta burst stimulation protocols.
- The effects of Aβ(1-42), human amylin, and AC253 on LTP were assessed in both wild-type and TgCRND8 mice.
Main Results:
- Aβ(1-42) and human amylin significantly reduced LTP, while the reverse sequence Aβ(42-1) had no effect.
- AC253 pretreatment prevented the Aβ- and amylin-induced LTP reduction without altering baseline transmission or normal LTP.
- TgCRND8 mice exhibited blunted LTP, which was significantly improved by AC253 administration.
Conclusions:
- The study demonstrates that Aβ(1-42) and human amylin impair LTP through the amylin receptor.
- Blocking the amylin receptor with AC253 enhances LTP in a mouse model of increased brain amyloid burden.
- Amylin receptor antagonists represent a promising therapeutic strategy for Alzheimer's disease.
Related Concept Videos
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression
Alzheimer Disease ll: Pathophysiology
Role of Amygdala in Memory
One of the...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

